Lyrica
Product Images NDC 52959-891

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Lyrica (NDC 52959-891). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by H.j. Harkins Company, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (50 mg Capsule Bottle)

Lyrica 50mg capsule label showing NDC 52959-891-30, manufactured by Pfizer at Vega Baja, PR, with lot number LYR510PZ and expiration date 11/12. The label includes a note to take as directed by a doctor and lists comparison information to NDC 0071-1013-68. The label also features multiple smaller labels indicating quantity of 30 capsules each.*

FDA Label Image

Principal Display Panel (75 mg Capsule Bottle)

Packaging label for Lyrica 75 mg capsule by H.J. Harkins Company, Inc., manufactured by Pfizer at Vega Baja, PR. Label shows lot number LYC05PZ, expiration date 08/10, and NDC 52959-747-30. Capsule described as white/orange. Includes caution regarding prescription use and storage instructions.*

FDA Label Image

Principal Display Panel (100 mg Capsule Bottle)

Lyrica 100mg Capsule packaging label displaying the lot number LIR104PZ, manufacturer Pfizer, and expiration date 10/10. The label includes a comparison to Mfg. NDC 0071-1015-68 and identifies the pill as an orange capsule. The container holds 30 capsules. Additional text includes usage instructions and a federal law caution about prescription dispensing.*

FDA Label Image

Principal Display Panel (150 mg Capsule Bottle)

Lyrica 150mg capsule packaging label showing the NDC 52959-897-30. The label states the lot number LRC155PZ, manufacturer Pfizer, and expiration date 04/10. Manufactured in Baja Vega, PR, with a white round capsule pill identification. The label advises to take as directed by a doctor and includes multiple smaller identical labels on the right side. The labeler is H.J. Harkins Company, Inc.*

FDA Label Image

Figure (Lyrica 01)

A text panel showing a formula for calculating creatinine clearance (CLCr), which includes variables for age, weight, serum creatinine, and a factor adjustment for female patients. The formula is presented as a mathematical expression with units in years, kilograms, and mg/dL.*

FDA Label Image

Chemical Structure (Lyrica 02)

Chemical structure diagram of the active ingredient in Lyrica, depicting its molecular formula with details including an amino group, carboxyl group, and multiple carbon chains in a three-dimensional arrangement.*

FDA Label Image

Figure (Lyrica 03)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo, illustrating their relative efficacy in pain improvement.*

FDA Label Image

Figure (Lyrica 04)

A line graph depicting the percent of patients improved versus the percent improvement in pain from baseline. The graph compares two groups: Pregabalin 100 mg three times a day and placebo, showing higher patient improvement with Pregabalin across various pain improvement percentages.*

FDA Label Image

Figure (Lyrica 05)

A line chart depicting the percent of patients improved against percent improvement in pain from baseline. The chart compares four groups: Pregabalin 300 mg twice a day, Pregabalin 150 mg twice a day, Pregabalin 75 mg twice a day, and placebo, showing variation in patient improvement percentages across different pain improvement levels.*

FDA Label Image

Figure (Lyrica 06)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph illustrates comparative pain improvement outcomes for Lyrica's active ingredient dosing versus placebo.*

FDA Label Image

Figure (Lyrica 07)

A line graph depicting the percent of patients improved compared to the percent improvement in pain from baseline. It compares three lines for Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo showing differing levels of patient improvement over varying pain improvement percentages.*

FDA Label Image

Figure (Lyrica 08)

Bar chart displaying Responder Rate (%) across different treatments in two studies (E1 and E3). The X-axis lists groups including Placebo, 50 mg/day, 300 mg/day, 600 mg/day, 8 ID, 5 ID, and 11 ID. The Y-axis shows percentages from 0% to 60%. Statistically significant differences versus placebo are indicated.*

FDA Label Image

Figure (Lyrica 09)

A line chart depicting seizure reduction (median percentage change from baseline) by dose (mg/day). It includes data points from four studies labeled Study E1 BD, Study E2 TID, Study E3 BID, and Study E3 TID, showing increasing seizure reduction with higher doses up to 600 mg/day. The chart notes p-values for statistical significance at various dose levels, illustrating efficacy trends with increasing dosage.*

FDA Label Image

Figure (Lyrica 10)

A line graph showing the percent of patients improved plotted against percent improvement in pain from baseline for Lyrica (pregabalin) daily doses of 300 mg, 450 mg, and 600 mg, compared to placebo. The graph includes four lines representing each dose and placebo, with two vertical lines highlighting specific percentage improvement points.*

FDA Label Image

Figure (Lyrica 11)

A survival curve chart comparing the estimated percentage of subjects without LTR (Likely Treatment Response) over 180 days between Pregabalin and Placebo groups. The x-axis represents days, and the y-axis represents the estimated percentage of subjects without LTR, with Pregabalin showing a higher survival rate than Placebo throughout the period.*

FDA Label Image

Logo (Lyrica 12)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.